First report of safety/efficacy of sotorasib + pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC
Using sotorasib as a lead-in therapy with pembrolizumab or atezolizumab for patients with advanced KRAS p.G12C non-small cell lung cancer demonstrated durable clinical activity with lower rates of grade 3-4 treatment-related ...
Aug 8, 2022
0
8